Efficacy of a combined alendronate and calcitriol agent (Maxmarvil®) in Korean postmenopausal women with early breast cancer receiving aromatase inhibitor: a double-blind, randomized, placebo-controlled study

Endocrine Journal

Byeong Woo Park¹  Seho Park¹  Sung-Kil Lim²  Hyung Seok Park¹  Yumie Rhee²  Kijun Song³ 

[1] Department of Surgery, Yonsei University College of Medicine, 120-752, Seoul, Korea;Department of Internal Medicine, Endocrine Research Institute, and Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, 120-752, Seoul, Korea;Department of Biostatistics, Yonsei University College of Medicine, 120-752, Seoul, Korea

关键词: Aromatse inhibitor;    Alendronate;    Calcitriol;    Combinative agent;    Osteoporosis;   

DOI  :  10.1507/endocrj.EJ12-0283

学科分类：内分泌与代谢学

来源: Japan Endocrine Society

【 摘 要 】

References(16)Cited-By(3)The use of aromatase inhibitor (AI) in postmenopausal women with hormone receptor (HR)-positive early breast cancer (EBC) produces a deleterious effect on bone mass and an increase in fractures.Several studies using intravenous bisphosphonates have shown effective management of AI-induced bone loss.To determine whether a lower dosage in oral form combined with calcitriol can effectively manage AI-induced bone loss, we performed a randomized, double-blind, prospective, placebo-controlled 24-week trial with a combination of alendronate and 0.5-μg of calcitriol daily to HR-positive EBC patients.A total of 98 Korean postmenopausal women with HR-positive EBC who received daily AI, calcium and vitamin D were randomly assigned to 5-mg of alendronate and 0.5-μg of calcitriol (Maxmarvil®) or placebo groups.The bone mineral density (BMD) and turnover markers were measured.At week 24, the difference in lumbar BMD between the groups was 3.0% (p vs. 109.8 ± 28.6%, p < 0.05).Our study demonstrates that a combination of 5-mg alendronate and 0.5-μg calcitriol is effective to prevent bone loss due to AI in Korean postmenopausal women with EBC.

【 授权许可】

Unknown